Drug intelligence / Profile preview

S-idazoxan

Development stage: Unknown
Lead developer: Terran Biosciences
Modality: Small Molecules
Administration: Oral

Overview

S-idazoxan is an enantiomerically pure form of idazoxan, a small molecule that functions as a selective alpha-2 adrenergic receptor antagonist and an imidazoline receptor modulator. Developed by Terran Biosciences, an extended-release formulation (TR-01-XRS) is currently in Phase 1 clinical trials to address the short half-life of the racemic compound and enable once-daily dosing. It is being investigated for its potential therapeutic effects in neurological and psychiatric diseases, including schizophrenia and Alzheimer's disease.

Other names: S-Idazoxan HCl Extended-Release

Targets

ADRA2C (α2C)ADRA2A (α2A)I2R (Imidazoline I2 receptor)I1R (Nischarin)ADRA2B (α2B)

Beyond the preview

Go deeper on S-idazoxan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-idazoxan.

Explore the full profile